110 related articles for article (PubMed ID: 18343750)
21. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration.
Radej J; Krouzecky A; Stehlik P; Sykora R; Chvojka J; Karvunidis T; Novak I; Matejovic M
Ther Drug Monit; 2011 Aug; 33(4):393-7. PubMed ID: 21654349
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.
Luke DR; Wood ND; Tomaszewski KE; Damle B
Nephrol Dial Transplant; 2012 Mar; 27(3):1207-12. PubMed ID: 21868395
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the effect of obesity on voriconazole serum concentrations.
Koselke E; Kraft S; Smith J; Nagel J
J Antimicrob Chemother; 2012 Dec; 67(12):2957-62. PubMed ID: 22915462
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
27. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.
Queiroz-Telles F; Goldani LZ; Schlamm HT; Goodrich JM; Espinel-Ingroff A; Shikanai-Yasuda MA
Clin Infect Dis; 2007 Dec; 45(11):1462-9. PubMed ID: 17990229
[TBL] [Abstract][Full Text] [Related]
28. Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies.
Lee YJ; Lee SO; Choi SH; Kim YS; Woo JH; Chun S; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
Med Mycol; 2013 Apr; 51(3):324-30. PubMed ID: 22712456
[TBL] [Abstract][Full Text] [Related]
29. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
Rüping MJ; Müller C; Vehreschild JJ; Böhme A; Mousset S; Harnischmacher U; Frommolt P; Wassmer G; Drzisga I; Hallek M; Cornely OA
Mycoses; 2011 May; 54(3):230-3. PubMed ID: 19889174
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
Chan HM; Duran SH; Walz PH; Ravis WR
J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087
[TBL] [Abstract][Full Text] [Related]
31. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
32. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice.
Heinz WJ; Silling G; Böhme A
Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange.
Spriet I; Brüggemann RJ; Annaert P; Meersseman P; Van Wijngaerden E; Lagrou K; Willems L
Ther Drug Monit; 2013 Feb; 35(1):141-3. PubMed ID: 23296095
[TBL] [Abstract][Full Text] [Related]
34. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
[TBL] [Abstract][Full Text] [Related]
35. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy.
Claus BO; Hoste EA; Colpaert K; Robays H; Decruyenaere J; De Waele JJ
J Crit Care; 2013 Oct; 28(5):695-700. PubMed ID: 23683557
[TBL] [Abstract][Full Text] [Related]
36. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients.
Gómez-López A; Cendejas-Bueno E; Cuesta I; García Rodríguez J; Rodríguez-Tudela JL; Gutiérrez-Altés A; Cuenca-Estrella M
Med Mycol; 2012 May; 50(4):439-45. PubMed ID: 22070341
[TBL] [Abstract][Full Text] [Related]
37. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*.
Udy AA; Baptista JP; Lim NL; Joynt GM; Jarrett P; Wockner L; Boots RJ; Lipman J
Crit Care Med; 2014 Mar; 42(3):520-7. PubMed ID: 24201175
[TBL] [Abstract][Full Text] [Related]
38. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
Chishimba L; Niven RM; Cooley J; Denning DW
J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
[TBL] [Abstract][Full Text] [Related]
39. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
40. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
